Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions

American Heart Journal

Volumn 146, Issue 2, 2003, Pages 345-350

  Best, Patricia J M ^a   Lennon, Ryan ^a   Gersh, Bernard J ^a   Ting, Henry H ^a   Rihal, Charanjit S ^a   Bell, Malcolm R ^a   Herzog, Charles A ^b   Holmes Jr , David R ^a   Berger, Peter B ^a  

^a MAYO CLINIC   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DRUG SAFETY; FEMALE; HEMATOCRIT; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0041488808     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00231-X     Document Type: Article

References (25)

1. Rubenstein MH, Harrell LC, Sheynberg BV, et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000;102:2966-72.
2. Best PJ, Lennon R, Ting HH, et al. Even mild renal insufficiency is associated with increased mortality after percutaneous coronary interventions [abstract]. J Am Coll Cardiol 2001;28:75A.
3. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61.
4. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-96.
5. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-35.
6. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829-35.
7. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
8. Ryan TJ, Faxon DP, Gunnar RM, et al. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on percutaneous transluminal coronary angioplasty). Circulation 1988;78:486-502.
9. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinates of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation 1990;82:1193-202.
10. Wolfe RA, Port FK, Webb RL, et al. Excerpts from the United States Renal Data System 1998 annual data report: V. patient mortality and survival. Am J Kidney Dis 1998;32(Suppl 1):S69-80.
11. Chertow GM, Normand SL, Silva LR, et al. Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project. Am J Kidney Dis 2000;35:1217-20.
12. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. New Engl J Med 1998;339:799-805.
13. Ting HH, Tahirkheli NK, Berger PB, et al. Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure. Am J Cardiol 2001;87:630-3.
14. Malyszko J, Malyszko JS, Pawlak D, et al. Hemostasis, platelet function and serotonin in acute and chronic renal failure. Thromb Res 1996;83:351-61.
15. Di Minno G, Martinez J, McKean ML, et al. Platelet dysfunction in uremia: multifaceted defect partially corrected by dialysis. Am J Med 1985;79:552-9.
16. Soslau G, Brodsky I, Putatunda B, et al. Selective reduction of serotonin storage and ATP release in chronic renal failure patients platelets. Am J Hematol 1990;35:171-8.
17. Sreedhara R, Itagaki I, Hakim RM. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am J Kidney Dis 1996;27:355-64.
18. Liani M, Salvati F, Golato M, et al. Platelet glycoproteins GPIb and GPIIb/IIIa abnormalities in uremia. Nephron 1996;68:442-8.
19. Gafter U, Bessler H, Malachi T, et al. Platelet count and thrombopoietic activity in patients with chronic renal failure. Nephron 1987;45:207-10.
20. Noris M, Benigni A, Boccardo P, et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 1993;44:445-50.
21. Gordge MP, Faint RW, Rylance PB, et al. Platelet function and the bleeding time in progressive renal failure. Thromb Haemost 1988;60:83-7.
22. Mezzano D, Tagle R, Pais E, et al. Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure. Thromb Res 1997;88:465-72.
23. Hergesell O, Andrassy K, Geberth S, et al. Plasma thrombomodulin levels are dependent on renal function. Thromb Res 1993;72:455-8.
24. Mezzano D, Tagle R, Panes O, et al. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 1996;76:312-21.
25. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.